Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant.
OBJECTIVE
To compare the international normalized ratios (INRs) of patients positive for lupus anticoagulant and the INRs of control patients receiving warfarin therapy with equivalent therapeutic chromogenic factor X levels.


METHODS
Prospective case series.


METHODS
A 625-bed, adult, private, tertiary care teaching hospital.


METHODS
Sixty-eight outpatients positive for lupus anticoagulant and 57 control patients receiving long-term warfarin therapy.


RESULTS
Concomitant INR and chromogenic factor X activity were measured in all patients. In 44 control patients (77%) and 46 patients with lupus anticoagulant (68%), chromogenic factor X activity was 22-40% of normal, which is therapeutic. Of the 44 control patients, 4 (9%) had an INR above 3.0, and none had an INR above 4.0. In contrast, 18 (39%) of the 46 patients with lupus anticoagulant had an INR above 3.0, and 5 (11%) had an INR above 4.0.


CONCLUSIONS
At least 10% of patients with lupus anticoagulant receiving long-term warfarin therapy may have falsely high INR values, which could lead to inappropriate warfarin dosage reduction. Monitoring warfarin therapy by chromogenic factor X activity in patients with lupus anticoagulant avoids this INR artifact.
Medical Education Department, Abbott Northwestern Hospital, Minneapolis, Minnesota 55407, USA.
Terry K
TK
Rosborough
Michele F
MF
Shepherd
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D019934:International Normalized Ratio / Q000592:standards*; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015203:Reproducibility of Results; D018709:Statistics, Nonparametric; D014859:Warfarin / Q000627:therapeutic use*
D016682:Lupus Coagulation Inhibitor; D014859:Warfarin